
ABSTRACT OF THE DISCLOSURE

A3
10009475-121101

Ophthalmic ointments for treating infective eye diseases which are particularly effective against infective eye diseases caused by methicillin-resistant *Staphylococcus aureus* (MRSA) or methicillin-resistant *Staphylococcus epidermidis* (MRSE) and contain as the active ingredient from 0.01 to 5.0% of vancomycin hydrochloride. Compared with intravenous administration, topical administration of these ophthalmic ointments is accompanied with no problem of the occurrence of side effects such as renal toxicity and thus enables the maintenance of a therapeutically effective concentration.
